文献速递肾小球疾病

IgA肾病蛋白尿随时间变化与疾病进展的队列研究

Time-Varying Proteinuria and Progression of IgA Nephropathy: A Cohort Study.
PubMed 文献 · Am J Kidney Dis · 2024-02-15

该单中心观察性队列纳入1530例IgA肾病患者,采用边际结构模型分析时间更新蛋白尿(TVP)与复合肾脏结局的关联。中位随访43.5个月,254例(16.6%)发生复合结局;TVP≥0.5g/d风险升高,且基线蛋白尿≥1.0g/d者风险更显著。

要点

  • TVP≥0.5g/d与复合肾脏结局风险升高相关,且呈分级关联。
  • 基线蛋白尿≥1.0g/d者,TVP 0.3–<0.5g/d即风险升高。
  • 基线蛋白尿<1g/d者,TVP≥1.0g/d时风险才开始升高。

核心结论

  • IgA肾病患者TVP≥0.5g/d与肾脏衰竭风险升高相关,基线蛋白尿≥1.0g/d者风险更明显。

研究设计与样本

  • 观察性队列研究,纳入北京大学第一医院1530例IgA肾病患者,随访至少12个月。
  • 采用边际结构模型分析时间更新蛋白尿(TVP)与复合肾脏结局的关联。

主要发现

  • 中位随访43.5(IQR 27.2-72.8)个月,254例(16.6%)发生复合肾脏结局。
  • 与TVP<0.3g/d相比,0.3–<0.5、0.5–<1.0、1.0–<2.0、≥2.0g/d的HR分别为2.22(95%CI 0.88-5.58)、4.04(95%CI 1.93-8.46)、8.46(95%CI 3.80-18.83)、38.00(95%CI 17.62-81.95)。
  • 基线蛋白尿≥1.0g/d者,TVP 0.3–<0.5g/d较<0.3g/d的HR为3.26(95%CI 1.07-9.92,P=0.04)。
  • 基线蛋白尿<1g/d者,TVP≥1.0g/d较<0.3g/d的HR为3.25(95%CI 1.06-9.90)。

临床怎么用

  • IgA肾病治疗中蛋白尿目标可能需要低于1g/d,尤其基线蛋白尿≥1.0g/d者应关注TVP≥0.5g/d的风险。
  • 基线蛋白尿<1g/d者,TVP≥1.0g/d时风险升高,提示仍需控制蛋白尿至更低水平。

局限性

  • 单中心观察性研究,存在选择偏倚和未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Proteinuria is a surrogate end point for predicting long-term kidney outcomes in IgA nephropathy (IgAN) with levels<1g/day identified as a therapeutic target. However, this threshold has not been sufficiently studied. We quantified the associations of progression of IgAN with various levels of proteinuria. STUDY DESIGN: Observational cohort study. SETTING & PARTICIPANTS: 1,530 patients with IgAN and at least 12 months of follow-up at Peking University First Hospital. EXPOSURE: Proteinuria levels updated over time (time-varying proteinuria, TVP). OUTCOME: A composite kidney outcome of a 50% reduction in the estimated glomerular filtration rate or end-stage kidney disease. ANALYTICAL APPROACH: Marginal structural models. RESULTS: After a median follow-up period of 43.5 (IQR, 27.2-72.8) months, 254 patients (16.6%) developed the composite kidney outcome. A graded association was observed between TVP and composite kidney outcomes with higher risk among those with proteinuria of≥0.5g/day. Compared with TVP<0.3g/day, the HRs for proteinuria levels of 0.3 to<0.5g/day, 0.5 to<1.0g/day, 1.0 to<2.0g/day, and≥2.0g/day were 2.22 (95% CI, 0.88-5.58), 4.04 (95% CI, 1.93-8.46), 8.46 (95% CI, 3.80-18.83), and 38.00 (95% CI, 17.62-81.95), respectively. The trend was more pronounced in patients with baseline proteinuria of≥1.0g/day, among whom a higher risk was observed with TVP of 0.3 to<0.5g/day compared with TVP<0.3g/day (HR, 3.26 [95% CI, 1.07-9.92], P=0.04). However, in patients with baseline proteinuria levels of<1g/day, the risk of composite kidney outcome only began to increase when TVP was≥1.0g/day (HR, 3.25 [95% CI, 1.06-9.90]). LIMITATIONS: Single-center observational study, selection bias, and unmeasured confounders. CONCLUSIONS: This study showed that patients with IgAN and proteinuria levels of>0.5g/day, have an elevated risk of kidney failure especially among patients with proteinuria levels≥1.0g/day before initiating treatment. These data may serve to inform the selection of proteinuria targets in the treatment of IgAN. PLAIN-LANGUAGE SUMMARY: The presence of proteinuria has often been considered a surrogate end point and a possible therapeutic target in clinical trials in IgA nephropathy (IgAN). Some guidelines recommend a reduction in proteinuria to<1g/day as a treatment goal based on the results of previous longitudinal studies. However, these findings may have been biased because they did not properly adjust for time-dependent confounders. Using marginal structural models to appropriately account for these confounding influences, we observed that patients with IgAN and proteinuria levels≥0.5g/day have an elevated risk of kidney failure, especially among patients who had proteinuria levels of≥1.0g/day before initiating treatment. These data may serve to inform the selection of proteinuria targets in the treatment of IgAN.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Tang C, Chen P, Si FL, et al. Time-Varying Proteinuria and Progression of IgA Nephropathy: A Cohort Study. Am J Kidney Dis. 2024. PMID: 38364955. doi:10.1053/j.ajkd.2023.12.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。